MIGUEL JOSÉ
MARTÍN JIMÉNEZ
Catedrático de universidad
![Foto de MIGUEL JOSÉ](/img/nophoto.png)
![Foto de Universitat de Barcelona](/img/noimage_org.png)
Universitat de Barcelona
Barcelona, EspañaPublicacions en col·laboració amb investigadors/es de Universitat de Barcelona (8)
2024
-
Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey
Clinical and Translational Oncology, Vol. 26, Núm. 8, pp. 2060-2069
2023
-
Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper
Revista Espanola de Quimioterapia, Vol. 36, Núm. 1, pp. 1-25
-
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)
Breast cancer research : BCR, Vol. 25, Núm. 1, pp. 2
2022
-
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer
Cancer Treatment Reviews, Vol. 111
-
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
Breast, Vol. 66, pp. 77-84
2019
-
A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study
Investigational New Drugs, Vol. 37, Núm. 1, pp. 98-108
2017
-
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2- negative breast cancer
Oncotarget, Vol. 8, Núm. 13, pp. 21930-21937
2015
-
Population-based multicase-control study in common tumors in Spain (MCC-Spain): Rationale and study design
Gaceta Sanitaria, Vol. 29, Núm. 4, pp. 308-315